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ABSTRACT 
A sensitive, fast, and stability-indicating gradient reverse-phase liquid chromatography method was 
developed for quantitative simultaneous estimation of Pyrantel pamoate, Praziquantel and Febantel using 
reverse phase high performance liquid chromatography by  gradient elusion with dual wavelength at  a 
specified time interval. All three ingredients were well separated with Phenominax Hypersil C18 (ODS) (4.6 
X100mm) 3µm column. The various factors affecting different parameters during method development by 
HPLC was analyzed and standardized. 




Three active ingredients having different mode of action 
and spectra of activity namely Praziquantel Pyrantel 
pamoate and  Febantel  present in single dosage form as 
tablet containing 68.0 mg Praziquantel, 68.0 mg 
Pyrantel base as Pyrantel Pamoate and 340.2 mg 
Febantel  was used for the simultaneous estimation. 
Praziquantel is active against cestodes (tapeworms). 
Pyrantel Pamoate is active against hookworms and 
ascarids. Pyrantel Pamoate acts on the cholinergic 
receptors of the nematode resulting in spastic paralysis 
i.e.  Peristaltic action of the intestinal tract then 
eliminates the parasite. Febantel is active against 
nematode parasites including whipworms. Febantel is 
rapidly absorbed and metabolized in the animal [1, 2]. 
Pyrantel Pamoate is Yellow to tan solid, practically 
insoluble in water (Solubility of <0.1 g/100 mL at water 
19 ºC ) & methanol; soluble in dimethyl sulfoxide; 
slightly soluble in dimethyl formamide. Molecular 
Formula is C34H30N2O6S, Molecular weight: 594.68 [3]. 
Praziquantel is white crystalline powder very slightly 
soluble in water (water solubility 400 mg/L); freely 
soluble in alcohol & in chloroform. Molecular formula 
is C19H24N2O2, Molecular weight: 312.41 [3]. Febantel is 
white or almost white, crystalline powder practically 
insoluble in water (is soluble in 1 to 2 ppm in water at 
pH 5 to 9), soluble in acetone, slightly soluble in 
anhydrous ethanol. Molecular formula is C20H22N4O6S. 
Molecular weight: 446.48 [4].  
The proposed method for separation of these three 
molecules is reverse phase method. Reversed phase 
HPLC (RP-HPLC) has a non-polar stationary phase and 
polar mobile phase. In Reverse phase liquid 
chromatography the separation of molecules is based 
upon their inter-action with a hydrophobic matrix which 
is largely based on their polarity. Molecules are bound 
to the hydrophobic matrix in an aqueous buffer (polar) 
and eluted from the matrix using a gradient of organic 
solvent (non-polar). One common stationary phase is 
silica. Silica beads (3-5 micron) have linear octadecane 
groups (C18) attached to the surface via co-valent 
bonds. These beads are usually porous in order to 
increase the surface area of the beads available for 
binding. The C18 groups are very hydrophobic (non-
polar) and can bind quite polar molecules such as 
charged peptides in a highly polar solvent such as water. 
Silica has been surface-modified with RMe2SiCl, where 
R is a straight chain alkyl group such as C18H37 or 
C8H17. Generally n-Octadecyl(RP-18),n-octyl ( RP-
8).ethyl (RP-2), phenyl,(CH2)n-CN, (CH2)n-Diol.  
hydrophobic polymers can be used as stationary phase. 
In these stationary phases nonpolar molecules retention 
time is longer than the polar molecules. [5,6,7]. 
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METHOD 
Fluconazole was supplied as gift sample from 
(Synergene Active Ingredients (p) ltd.), curcumin was 
procured from (molychem pvt Ltd.), ethanol from 
(Rankem lab, Mumbai), HPMC& carbapol, Peptone 
purchased from (Sd Fine Chem. Limited), Agar from 
(Lobachem), Sodium chloride, Glycerine, yeast extract 
& Beef extract were purchased from  (Molychem pvt 
Ltd). 
To develop the method for simultaneous estimation of 
Pyrantel Pamoate, Praziquantel and Febantel different 
experiments were carried out using different diluents. 
Different concentrations of drug were injected at 
different wavelengths for simultaneous estimation using 
different mobile phase to optimize the method.  A few 
of these trials are presented in this article to understand  
the  effect of different factors affecting in this method. 
The method development was started with solubility 
determination. As described earlier Pyrantel Pamoate, 
Praziquantel and Febantel are practically insoluble in 
water. So organic solvents in combination with 
phosphate buffer and surfactant were used to dissolve. 
For  optimization of chromatographic conditions the 
method development was started using  different 
columns like  Symmetry C18 waters 150X4.6mm, 5µ; 
Kromasil 100-5C18,150X4.6 mm; Phenomenex Gemini 
C18 250 x 4.6 mm , 5 µ particle size) & Phenominax 
Hypersil C18 (ODS) 100X4.6 mm,3µm.All three 
ingredients were well separated  with Phenominax 
Hypersil C18 (ODS) 100X4.6 mm, 3µm column. 
 
Preparation of Mobile Phase 
Buffer preparation: Accurately weighed 1.0 gm of 1-
Heptane sulphonic acid sodium salt and dissolved in 
950 ml of water, Added 1.0 ml of TEA and then 
adjusted to pH 7 with OPA and made up the volume up 
to 1000 ml with water. Filtered the buffer with 0.45 µ 
nylon filter. 
Diluent Preparation: 
Buffer preparation: Buffer solution was prepared by 
dissolving 3.12 gm of Sodium dihydrogen phosphate 
dihydrate in 1500 ml of water. 40 gm of Sodium lauryl 
sulfate was dissolved and sonicated for 30 minutes to 
dissolve completely. pH of the solution was adjusted up 
to   6.8  with dilute NaOH (50 % solution )  and made 
the volume up to 2000 ml with water. 
Diluent 1 was prepared by mixing above Buffer and 
Acetonitrile at the ratio of 20 : 80. 
Diluent 2 was prepared by mixing Acetonitrile, Glacial 
acetic acid, water and Tri ethyl Amine at the ratio of   
92.8 : 3 : 3: 1.2  . 
 
Preparation of blank solution: Diluent 1was taken in  
50ml volumetric flask by maintaining the temperature  
about   25° C . 10 ml of this diluent 1 was taken 
separately in to 50 ml volumetric flask and diluted up to 
the mark with diluent 2 and mixed. 2.5 ml from this 
preparation was taken in to 10ml volumetric flask and 
diluted with diluent 2 and mixed. This solution was 
taken as blank. 
 
Preparation of placebo solution: Accurately weighed 
placebo powder equivalent to 51 mg Pyrantel Pamoate, 
51mg Praziquantel and 255.15mg Febantel  was taken 
into  50 ml volumetric flask. 25 ml diluent 1 was added 
and sonicated till it dissolved completely by maintaining 
the temperature at 25° C and made volume up to the 
mark with Diluent 1 and mixed. The solution was 
filtered with SY25TG filter and few ml of filtered 
solution was discarded. From the filtered solution 
second stock solution was prepared which was further 
diluted to obtain the final test solution. 
Second stock preparation: 10 ml of above stock was 
taken separately in to 50 ml volumetric flask and diluted 
up to the mark with diluent 2 and mixed. 
Final test solution preparation: 2.5 ml from above 
stock preparation was taken in to 10ml volumetric flask 
and diluted with diluent 2 and mixed. 
 
Preparation of standard solution: 
Pyrantel Pamoate stock preparation: Accurately 
weighed about 51 mg of Pyrantel  Pamoate Working 
standard in  50ml volumetric flask.  25 ml diluent 1 was 
added and sonicated till it dissolved completely by 
maintaining the temperature   at about 25° C and made 
volume up to the mark with diluent 1 and mixed.  
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Praziquantel stock preparation: Accurately weighed 
about 51 mg of Praziquantel working standard in  50ml 
volumetric flask  . 25 ml diluent 1 was added and 
sonicated till it dissolved completely by maintaining the 
temperature at about 25° C and made volume up to the 
mark with diluent 1 and mixed.  
Febantel stock preparation: Accurately weighed about 
255.15 mg of Febantel Working standard in  50ml 
volumetric flask. 10 ml diluent 1 was added and 
sonicated till it dissolved completely by maintaining the 
temperature at about 25° C and made volume up to the 
mark with diluent 1 and mixed.  
Standard stock preparation: 10 ml of Pyrantel stock 
preparation, 10 ml of Praziquantel stock preparation and 
10 ml of Febantel stock preparation was taken 
separately in to 50 ml volumetric flask and  diluted up 
to the mark with diluent 2 and mixed.  
Working Standard Preparation: 2.5 ml from standard 
stock preparation was taken in to 10ml volumetric flask 
and diluted with diluent 2 and mixed.  
 
Preparation of test solution: 
Stock solution preparation: Twenty Tablets were 
weighed and average weight was determined. These 
tablets were triturated in a mortar pestle and transferred 
an  accurately weighed tablet powder equivalent to 51 
mg Pyrantel Pamoate, 51mg Praziquantel and 255.15 
mg Febantel  in to 50 ml volumetric flask. 25 ml diluent 
1 was added and sonicated till it dissolved completely 
by maintaining the temperature at 25° C and made 
volume up to the mark with diluent 1 and mixed. The 
solution was filtered with SY25TG filter and few ml of 
filtered solution was discarded. From the filtered 
solution second stock solution was prepared which was 
further diluted to obtain the final test solution. 
Second stock preparation: 10 ml of above test stock 
was taken separately in to 50 ml volumetric flask and 
diluted up to the mark with diluent 2 and mixed. 
Final test solution preparation: 2.5 ml from standard 
stock preparation was taken in to 10ml volumetric flask 
and diluted with diluent 2 and mixed. 
 
Figure 1: Chromatogram for mixture of all three standards of Trial 4 at  300 nm 
 
Figure 2: Chromatogram for  mixture of standards of Trial 4  at 210 nm 
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Table 1: Chromatographic conditions & System Suitable Parameters  (Isocratic trial) 
Chromatographic 
conditions 
Column Phenomenax Hypersil  C18 (ODS) (4.6 x 100 mm) 3 µm 
MP 60:30:10 (Acetonitrile , buffer and methanol) 
F rate 1.5 ml/min 
C Temp  25°C 
Inj vol 10 µl 
Wavelength 210nm & 300 nm 
Description Trial 1 Trial 2 Trial 3 Trial 4 
Name of Components Praziquantel  Pyrantel Febantel Praziquantel  Pyrantel Febantel 
Area 2479 1371334 35696511 2463406 25899196 9189041 
RT 1.89 0.87 2.71 1.89 0.87 2.72 
Tailing Factor 1.34 1.59 1.63 1.33 2.34 1.36 
Theoretical plates 1754 672 2557 1701 489 1971 
 
Table 2: Chromatographic conditions & System Suitable Parameters  (Isocratic trial) 
Chromatographic 
conditions 
MP 60:30:10 (Acetonitrile , buffer and methanol) 
F rate 1.0 ml/min 
C Temp  25°C 
Inj vol 10 µl 
Wavelength 210nm & 300nm 
Description Trial 5 Trial 6 Trial 7 Trial 8 
Name of Components Praziquantel  Pyrantel Febantel Praziquantel  Pyrantel Febantel 
Area 2967 503669 8269729 559997 5362454 1607340 
RT 2.79 1.33 4.027 2.78 1.33 4.03 
Tailing Factor 1.05 1.07 1.29 1.24 1.07 1.25 
Theoretical plates 3172 787 2503 2346 675 2560 
MP: Mobile Phase, F Rate: Flow rate , RT: Retention Time, C Temp: Column Temp , Inj vol: Injection volume 
 
Figure 3 : Chromatogram for mixture of all  three standards of trial 8 at 300 nm 
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Figure 4: Chromatogram for mixture of all three standards of Trial 8 at 210 nm 
 
Trial 9 with same chromatographic conditions as table 2 with column temperature 45°C and mobile phase ACN and 
buffer in ratio of 40: 60 was taken 
 
Figure 5: Chromatogram for mixture of all three standards of trial 9 at 300 nm 
 
Figure 6: Chromatogram for mixture of all three standards of trial 9 at 210 nm  
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Table 3: Chromatographic conditions: Time –Gradient Programming  
Coloumn Phenomenax Hypersil C18 (ODS) (4.6 x 100 mm) 3 µm. 
Description Trial 10 Trial 11 Trial 12 Trial 13 Trial 14 Trial 15 Trial 16 
Flow rate (ml/min) 1.5 1.0 1.0 1.0 1.0 1.0 1.0 
Temperature 45°C 45°C 45°C 45°C 45°C 45°C 45°C 
Injection volume 10 µl 10 µl 10 µl 10 µl 10 µl 10 µl 10 µl 
Time-Gradient Programming Table 4 Table 5 Table 6 Table 7 Table 8 
Table 4: Time gradient programming for trial 10  
Minutes ACN Buffer 
0 20 80 
2 20 80 
2.5 50 50 
15 50 50 
Table 5: Time gradient programming for trial 11  
Minutes ACN Buffer 
0 30 70 
2 50 50 
8 50 50 
15 50 50 
Table 6: Time gradient programming for trial 12 
Minutes ACN Buffer 
0 30 70 
2 50 50 
8 50 50 
9 30 70 
Table 7: Time gradient programming for trial 13 
Minutes ACN Buffer 
0 30 70 
2 50 50 
8 50 50 
9 30 70 
10 70 70 
Table 8: Time gradient programming for trial 14 at 300 and 210 nm 
Time (min) ACN Buffer Wavelength 
0.00 30 70 300 nm 
2.00 50 50 300 nm 
2.10 - - 210 nm 
8.00 50 60 210 nm 
9.00 30 70 210 nm 
10.00 30 70 210 nm 
15.00 30 70 210 nm 
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Figure 7: Chromatogram for mixture of all three standards of trial 10 at  300 nm 
 
Figure 8: Chromatogram for mixture of all three standards of trial 10 at 210 nm 
  
Figure 9: Chromatogram for mixture of all three standards of trial 11 at 300 nm 
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Figure 10: Chromatogram for mixture of all three standards of trial 11 at 210 nm 
 
Figure 11: Chromatogram for mixture of all three standards of trial 12 at 300 nm 
 
Figure 12: Chromatogram for mixture of all three standards of trial 12 at 210 nm 
 




April- June 2014 Volume XI                              Issue 2 40
 
Figure 13: Chromatogram for mixture of all three standards of trial 13 at 300 nm 
 
Figure 14: Chromatogram for mixture of all three standards of trial 13 at 210 nm 
 
Figure 15: Chromatogram for Standard preparation (mixture of all three standards) at 300 and 210 nm 
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Table 9:  System suitability parameters of standard preparation 
Name RT Area Theoretical plates Tailing 
Pyrantel 1.32 400365 1987 1.55 
Praziquantel 4.79 1335470 6078       1.24 
Febantel 5.82 12754959 5743 1.26 
 
Figure 16: Chromatogram for test solution 
 
Table 10:  System suitability parameters for test solution 
Name RT Area Theoretical plates Tailing 
Pyrantel 1.350 388198 2000 1.57 
Praziquantel 4.788 1326217 6218 1.18 
Febantel 5.794 12899677 5800 1.192 
 
Figure 17: Chromatogram for placebo solution 
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RESULTS AND DISCUSSION 
The method development was started with solubility 
determination. Pyrantel Pamoate, Praziquantel and 
Febantel are practically insoluble in water.  In reverse 
phase chromatography acetonitrile (uv cut-off of 190) 
and methanol (UV cut-off 205) (MeOH) are commonly 
used solvents. These solvents are miscible with water. 
Sodium Lauryl Sulphate (SLS) is used as an anionic 
surfactant to increase the solubility of the molecules in 
combination of sodium phosphate buffer pH 6.8  and 
acetonitrile. This diluent is further diluted with mixture 
of acetonitrile, glacial acetic acid  and triethylamine. 
This mixture works as organic modifier that can alter 
selectivity and improve peak shape. All analytes have 
chromophor and are UV active, so UV detector was 
selected for method development. Organic solvent in 
mobile phase can decrease the retention time. Similarly 
retention time can be increased by adding more water or 
buffer. In the studied method, development is started 
with the mixture of acetonitrile and water as mobile 
phase, but satisfactory separation was not obtained. 
Hence buffer was used in combination with acetonitrile.  
In reversed phase HPLC, the retention of analyte is 
related to their hydrophobicity [6]. The more 
hydrophobic the analyte, the longer it is retained. When 
an analyte is ionized, it becomes less hydrophobic and, 
hence its retention decreases. Acids lose a proton and 
become ionized when pH increases and bases gain a 
proton and become ionized when pH decreases. 
Therefore, when separating mixtures containing acids 
and/or bases by reversed phase HPLC, it is necessary to 
control the pH of the mobile phase using an appropriate 
buffer in order to achieve reproducible results. In the 
studied method sodium phosphate buffer pH 6.8 was 
first tried to retain this compound without ion pair 
reagent, but could not be retained.So ion paring reagent 
1-Heptane Sulphonic acid sodium salt was used in the 
buffer for mobile phase preparation. Triethylamine was 
used as organic modifiers and orthophosphoric acid was 
used to adjust the pH of mobile phase to 7. The 
components were tried to separate using different 
columns and found that column with smaller size and 
low particle size provided better efficiency for 
separation and lower retention time. The separation was 
better obtained with Phenominax Hypersil C18 
(ODS)(4.6 X100mm) 3µm column.  
Initially isocratic method was used to understand the 
behavior of the individual molecules and also in 
combination at wave length 210 nm and 300 nm. For 
details refer table 1, 2 and figure 1,2,3,4,5, 6. In the 
fourth trial mixture of all three components were 
injected. All three peaks were separated and eluted but 
Pyrantel peak is merged with one unknown peak at 210 
nm. The results are tabulated in Table 1(Figure 1 and 
Figure 2). To overcome this problem of merging, the 
flow rate was decreased from 1.5ml/min to 1 ml/min in 
next trial. When flow rate was decreased the retention 
time was increased. This can be observed in the fifth, 
sixth and seventh trials. As a result of decreasing the 
flow rate of mobile phase the Pyrantel peak which was 
merged with the unknown peak is slightly separated 
without proper resolution. So in the ninth trial the ratio 
of mobile phase acetonitrile and buffer in the ratio was 
done 40:60.The column temperature was increased to 
45°C. The RT of Pyrantel, Praziquantel and Febantel are 
0.772, 2.865 and 9.022 min respectively, improper 
separation of Pyrantel peak at 300 nm. Febantel and 
Praziquantel peaks were too far with the problem of 
merging.(Figure 5  and  Figure 6) 
Elevated temperature was used to reduce analysis time 
and to improve peak shape. The temperature has a direct 
influence or the chromatographic result since it 
influences the RT and shape of the peak. The constant 
temperature can increase the robustness in HPLC, 
reproducible RT. Only at constant temperature RT are 
constant and results are comparable. At temperature 
above 50°C, an increased noise level was observed. 
Thus change in temperature can be used to control 
sample retention.  
Thus with isocratic methods satisfactory results were 
not observed due to improper shape of peaks and 
improper separation of components. A stronger mobile 
phase gives shorter run times and weaker gives the 
reverse of the same. Early bands require a weaker 
mobile phase, and latter are best separated with stronger 
mobile phase. Based on these observations, Time-
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gradient programming was studied further for 
simultaneous estimation of the three components and 
column oven temperature was increased to overcome 
the problem of merging. In the tenth trial different ratio 
of acetonitrile and buffer was used at flow rate of 1.5 
ml/min. The temperature of the column was 45°C. 
Higher tailing of Pyrantel peak was observed at these 
chromatographic conditions at 300 nm (Table 3 & 4 and 
Figure 7 and Figure 8). In the eleventh and twelfth 
trials flow rate of mobile phase was again changed to 1 
ml/min.  Merging Peak of Pyrantel peak at 300 nm was 
observed which may be saturation issue.  (Table 3, 5, 6 
and Figure 9, Figure 10, Figure 11 and Figure 12).In the 
thirteenth trial Praziquantel and Febantal peak was not 
well separated. (Table 3 & 7  and  Figure 13 and  Figure 
14). Based on these observations, in the next trials the 
ratio of mobile phase was varied at different time 
intervals and duel wavelength was used. In the 
fourteenth trial, mixture of all three components were 
injected using Phenomenax Hypersil  C18 (ODS) (4.6 x 
100 mm) 3 µm column. Detail of the time- gradient 
program of mixture of Acetonitrile and buffer was 
described on table 8.  Two wavelengths were selected to 
get proper separation .These wavelengths used were 
210nm & 300 nm. The wavelength in the detector was 
kept 300 nm initially and at 2.10 min the wavelength 
was changed to 210 nm. The temperature of the column 
was 45°C. All the components were well separated. The 
tailing factor was less than 2 as per compendia 
requirements. Peak shapes were satisfactory and RT was 
less than 10 minutes. In the fifteenth trial, test 
preparation was injected with the same chromatographic 
conditions as fourteenth trial. All the components were 
well separated. All the parameters are satisfactory 
(Table 10 and Figure 16). In the sixteenth trial, placebo 
preparation was injected in the same chromatographic 
conditions as fourteenth trial. No peak was obtained in 
the gradient (Figure 17).  
 
CONCLUSION 
From the above studies, it can be concluded that mobile 
phase, flow rate , column temperature and gradient 
programming affects simultaneous estimation of 
Pyrantel Pamoate, Praziquantel and Febantel by High 
Performance Liquid Chromatography. The three 
components can be well separated by gradient 
programming at wavelength 210 nm and 300 nm at an 
elevated temperature   of 45°C using C-18 column.  The 
run time is 15 min and retention time of Pyrental, 
Febental, Praziquental is 1.3, 4.7 and 5.8 min 
respectively that allows simultaneous estimation of the 
three components in a short period of time. The tailing 
factors were less than 2 for all the components and 
comply as per official compendia requirements. This 
method is also validated and detailed discussions shall 
be presented in the next article. Hence this method can 
be used for simultaneous separation, identification and 
quantitative estimation in quality control. 
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